" Artículos de la Revista de la Asociación Americana - Cuarta ...
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) Eric Van Cutsem, MD, PhD University Hospitals Gasthuisberg/Leuven, Leuven,
ANCO Best of ASCO 2011 GI Oncology Abstracts Katie Kelley, M.D. Assistant Clinical Professor University of California, San Francisco 27 August 2011.
GICS 2012 Final skin toxicity and patient ‑ reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1 st ‑ line metastatic.
Introduction
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer ( mCRC )
Management Advances for Differentiated and Medullary Thyroid Carcinoma
Axel Grothey , MD
